PFAS What Clinicians Should Know

This enduring activity is designed to increase knowledge and change competency of Per- and Polyfluorinated Substances, PFAS (forever chemicals) practices and strategies.

Learning Objectives:

At the conclusion of the session, the participant should be able to:

1. Define per- and polyfluoroalkyl substances (PFAS)
2. List the exposure pathways of PFAS
3. Describe the potential health effects of PFAS
4. Describe special issues regarding children affected by PFAS
5. Identify resources available to healthcare providers related to PFAS 
   
6. List 2 ways this educational activity will impact my team (joint accreditation objective)

Presented By:

Laurie Halmo, MD, FAAP
Assistant Professor,
University of Colorado School of Medicine

CE Origination date: April 17, 2023
CE Expiration date: April 17, 2025

Accreditation Statements:

In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and (Pediatric Environmental Health Specialty Unit (PEHSU). The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of (0.25) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for (0.25) nursing contact hours.

Disclosure: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.  

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.